The Chromosomal Aberration Test (CAT) is routinely employed as part of NPD and to meet regulatory expectation to screen the compounds (chemicals, impurities, pesticides, insecticides, food and feed additives etc) for their clastogenic potential to cells (human blood lymphocytes or mammalian cell lines in culture by evaluating the development gene/chromosome damage in the form of structural aberrations at chromosome level.
Cells in cultures will exposed to the compound of interest at different concentrations for shorter duration (3-6 hours) and continuously (1.5 cell cycle time) till harvesting. In shorter duration exposure, testing will be performed by supplying liver metabolizing enzymes to evaluate by products of compound and in other hand absence of metabolism support in shorter and continuous exposures to evaluate direct compound activity.
Positive results demonstrated as increase in the percentage of structural aberrations in comparison with concurrent controls. Increase can be statistically significant and/or dose-dependent.
Aurigene Pharmaceutical Services is
that provides contract research and manufacturing services
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.